308 related articles for article (PubMed ID: 25001638)
41. Ocular Drug Delivery - New Strategies for Targeting Anterior and Posterior Segments of the Eye.
Fangueiro JF; Veiga F; Silva AM; Souto EB
Curr Pharm Des; 2016; 22(9):1135-46. PubMed ID: 26675225
[TBL] [Abstract][Full Text] [Related]
42. Intravitreal, Subretinal, and Suprachoroidal Injections: Evolution of Microneedles for Drug Delivery.
Hartman RR; Kompella UB
J Ocul Pharmacol Ther; 2018; 34(1-2):141-153. PubMed ID: 29206556
[TBL] [Abstract][Full Text] [Related]
43. Minimally invasive microneedles for ocular drug delivery.
Thakur Singh RR; Tekko I; McAvoy K; McMillan H; Jones D; Donnelly RF
Expert Opin Drug Deliv; 2017 Apr; 14(4):525-537. PubMed ID: 27485251
[TBL] [Abstract][Full Text] [Related]
44. Applications of microneedles in delivering drugs for various ocular diseases.
Gupta P; Yadav KS
Life Sci; 2019 Nov; 237():116907. PubMed ID: 31606378
[TBL] [Abstract][Full Text] [Related]
45. Drug delivery systems for the eye.
Kearns VR; Williams RL
Expert Rev Med Devices; 2009 May; 6(3):277-90. PubMed ID: 19419285
[TBL] [Abstract][Full Text] [Related]
46. An updated patent review on ocular drug delivery systems with potential for commercial viability.
Srivastava R; Pathak K
Recent Pat Drug Deliv Formul; 2011 May; 5(2):146-62. PubMed ID: 21453249
[TBL] [Abstract][Full Text] [Related]
47. Episcleral drug film for better-targeted ocular drug delivery and controlled release using multilayered poly-ε-caprolactone (PCL).
Sun S; Li J; Li X; Lan B; Zhou S; Meng Y; Cheng L
Acta Biomater; 2016 Jun; 37():143-54. PubMed ID: 27071973
[TBL] [Abstract][Full Text] [Related]
48. Prodrugs and nanomicelles to overcome ocular barriers for drug penetration.
Gote V; Ansong M; Pal D
Expert Opin Drug Metab Toxicol; 2020 Oct; 16(10):885-906. PubMed ID: 32729364
[TBL] [Abstract][Full Text] [Related]
49. Overcoming ocular drug delivery barriers through the use of physical forces.
Huang D; Chen YS; Rupenthal ID
Adv Drug Deliv Rev; 2018 Feb; 126():96-112. PubMed ID: 28916492
[TBL] [Abstract][Full Text] [Related]
50. Recent advances in ophthalmic drug delivery.
Kompella UB; Kadam RS; Lee VH
Ther Deliv; 2010 Sep; 1(3):435-56. PubMed ID: 21399724
[TBL] [Abstract][Full Text] [Related]
51. Formulation to target delivery to the ciliary body and choroid via the suprachoroidal space of the eye using microneedles.
Kim YC; Oh KH; Edelhauser HF; Prausnitz MR
Eur J Pharm Biopharm; 2015 Sep; 95(Pt B):398-406. PubMed ID: 26036448
[TBL] [Abstract][Full Text] [Related]
52. Recent progress in ocular drug delivery for posterior segment disease: emphasis on transscleral iontophoresis.
Myles ME; Neumann DM; Hill JM
Adv Drug Deliv Rev; 2005 Dec; 57(14):2063-79. PubMed ID: 16310884
[TBL] [Abstract][Full Text] [Related]
53. Ocular drug delivery-eye on innovation.
Rupenthal ID; O'Rourke M
Drug Deliv Transl Res; 2016 Dec; 6(6):631-633. PubMed ID: 27766597
[No Abstract] [Full Text] [Related]
54. Novel strategies for anterior segment ocular drug delivery.
Cholkar K; Patel SP; Vadlapudi AD; Mitra AK
J Ocul Pharmacol Ther; 2013 Mar; 29(2):106-23. PubMed ID: 23215539
[TBL] [Abstract][Full Text] [Related]
55. The prominence of the dosage form design to treat ocular diseases.
Campos PM; Petrilli R; Lopez RFV
Int J Pharm; 2020 Aug; 586():119577. PubMed ID: 32622806
[TBL] [Abstract][Full Text] [Related]
56. Safety evaluation of ocular drug delivery formulations: techniques and practical considerations.
Short BG
Toxicol Pathol; 2008 Jan; 36(1):49-62. PubMed ID: 18337221
[TBL] [Abstract][Full Text] [Related]
57. Delivery of therapeutics for deep-seated ocular conditions - status quo.
Nguyen H; Eng S; Ngo T; Dass CR
J Pharm Pharmacol; 2018 Aug; 70(8):994-1001. PubMed ID: 29675844
[TBL] [Abstract][Full Text] [Related]
58. Dendrimers as a promising tool in ocular therapeutics: Latest advances and perspectives.
Rodríguez Villanueva J; Navarro MG; Rodríguez Villanueva L
Int J Pharm; 2016 Sep; 511(1):359-366. PubMed ID: 27436708
[TBL] [Abstract][Full Text] [Related]
59. Current and future ophthalmic drug delivery systems. A shift to the posterior segment.
Del Amo EM; Urtti A
Drug Discov Today; 2008 Feb; 13(3-4):135-43. PubMed ID: 18275911
[TBL] [Abstract][Full Text] [Related]
60. Targeted Nanotherapies for the Posterior Segment of the Eye: An Integrative Review on Recent Advancements and Challenges.
Gogoi NR; Marbaniang D; Pal P; Ray S; Mazumder B
Pharm Nanotechnol; 2022 Nov; 10(4):268-278. PubMed ID: 35946098
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
